SVP CMC (Chemistry, Manufacturing & Controls)
Jo joined NeRRe Therapeutics in August 2018 in a new role created to ensure significant senior CMC leadership for the Company and readiness of Orvepitant for Phase 3. Jo holds the same role SVP CMC for KaNDy Therapeutics. Jo is no stranger to NeRRe and previously held the role ‘Observer’ on the NeRRe board on behalf of GSK.
Prior to joining NeRRe, Jo spent over 30 years at GlaxoSmithKline where she was most recently VP of Technology & Strategy, Product Development & Supply. Her career has spanned many roles in CMC product development, achieving UK and global leadership. Specific successes include the CMC delivery of the sumatriptan portfolio for migraine and the dolutegravir portfolio for HIV. Jo went on to set up and lead a new global process robustness group at the interface of R&D and Manufacturing and has also headed the New Product Introduction Quality group.
Jo holds a BPharm (first class honours) from the School of Pharmacy, University College, London and is a registered Pharmacist. She is also an Eminent Fellow of the Academy of Pharmaceutical Sciences (APS), UK and an Advisor to the APS Board. Jo continues as a member of the Medicines Manufacturing Industry Partnership (MMIP) where she has been influential in aligning Pharma and UK Government on future areas for investment.